Is a Form 483 the same as a Warning Letter?

No. A Form 483 lists an FDA investigator’s observations at the close of an inspection; it is not a final agency determination. FDA may or may not follow up with a Warning Letter depending on the firm’s response and the severity of the findings.

Where can I read the full Form 483?

The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.

What is an FDA Form 483?

A Form FDA 483 lists an FDA investigator's written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.

Does this Form 483 mean Wells Pharma of Houston LLC violated the law?

No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.

FDA Form 483 — Wells Pharma of Houston LLC (April 13, 2026)

Here's the summary: FDA inspected Wells Pharma of Houston LLC in Texas and issued a Form 483 listing 4 inspectional observations following an inspection that concluded 2026-04-13. FDA records classify Wells Pharma of Houston LLC as a outsourcing facility. A Form 483 documents an investigator's findings at the close of an inspection under the Federal Food, Drug, and Cosmetic Act; it is not a final agency compliance determination. The observations on this page are drawn directly from the FDA-issued Form 483 record.

Key facts

Firm	Wells Pharma of Houston LLC
FEI / inspection ID	3016710931
Inspection end date	April 13, 2026
Citation count	4

What a Form 483 means

A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it.

Citations explained

Observation 1 — Procedures designed to prevent microbiological contamination of diug products pmp o1ting to

Procedures designed to prevent microbiological contamination of diug products pmp o1ting to be sterile are not established, written and followed. Specifically, A. Your fnm 's compounding technician was obse1ve d rem oving the bottle of sterile 4 '( b) < l from the inside of the ISO 5 LAFH, to the outside within the ISO 7 Cle amoom to disinfect their sterile 14 gloves and failing to re-disinfect the bottle of sterile'bl ~ prior to retmning it to the ISO 5 LAFH. Your fnm 's procedure Aseptic Material Transfer from CHC Ar ea into Classified Areas, HOU OPS-017, R evision 5 fail to adequately define a method for the transfer of steril ~(b) 4 < l bottles into and out of the ISO 5 LAF H. B. Your fnm 's compounding technicians were obse1ve d us ing hard to clean and disinfect pen within the ISO 7 Cleanroom to write within each production batch record that has the potential of.

Observation 2 — Dmg products failing to meet established specifications and quality control criteria are

Dmg products failing to meet established specifications and quality control criteria are n ot rejected. Specifically, during a review of your fnm 's compounded and distributed finished diug products, I found your fnm 's quality unit released and distributed, L ot# 091625104652129, Expi1y 1/16/2026 for Dextrose 50% (500MG/ML) Repackaged 50Mr.t>j Syringe Injectable 500MG/ML, which unde1went contract laborato1y testing, using an in conect USP monograph pH test method. The pH results were found to be within specification using the in conect test meth od . Due to a delay and inadequacy of an investigation by your fnm 's quality unit into the pH failure of the two (2) different batch es , Lot # 091625104652129 was released and distribute d. The quality unit's investigation was n ot expand ed to include a review of other finish ed di11g products to assess the potential of contract testing laborato1y test method not being accurate until this inspection's discussions with managemen t.

Observation 3 — Strict control is not exercised over labeling issued for use in diug

Strict control is not exercised over labeling issued for use in diug product labeling operations. Specifically, during a walk-through of your fnm's Labeling Production Area, I found an unsecured black storage filing cabinet containing issued printed CeFazolin labels for production use. Your fnm's phaimacist and quality unit repo1ied the key location for the unsecure unlocked cabinet was unknown at the time of the site walk-through. The area supervisor repo1ied that the labels were removed from the cabinet at the end of the shift and r eturned to the label printing cage. A review of your written procedures, Labeling Procedure, HOU-OPS-019, Revision 1; and Label Control, HOU-OPS-020, Revision l found the discussed process for label removal at shift end was n ot written within your fnm's procedures. The fnm's quality unit was unable to provide doc umentation of printed labels being removed from the unsecured black cabinet and be ing returned to the returned to the label printing cage. AM ENDMENT.

Observation 4 — The responsibilities and procedures applicable to the quality control unit are n

The responsibilities and procedures applicable to the quality control unit are n ot fully followe d. Specifically, A. Your fnm 's quality unit initiated CAPA HOU-2025-012 failed to adequately investigate and define coITections to secure and control finish ed product labeling and prevent mix-up within your fnm 's product labeling production area. For example, an unsecured cabinet containing CeFazolin labels was found in the labeling production area. Your fnm 's quality unit initiated CAPA-HOU-2026-008 after being made aware on March 17, 2026 during the labeling productions area walk-through. B. Your fnm 's quality unit lacks the responsibility to exercise control over documents that are either pending changes or in-process, obsolete procedures, or fo1m s, pending investigations, and other quality records, in a manner that would ensure that they stay in a state of contro l. On 3/17/2026, during a walk-through of your fnm in-process and finish ed diug refrigeration area, I found your fnm 's quality unit failed to collect,.

Wells Pharma of Houston LLC’s FDA history

Argus HQ has recorded 9 total FDA actions tied to Wells Pharma of Houston LLC: 0 warning letters, 7 recalls, 0 approval records, and 2 Form 483 inspection citations.

Frequently asked questions

Is a Form 483 the same as a Warning Letter?: No. A Form 483 lists an FDA investigator’s observations at the close of an inspection; it is not a final agency determination. FDA may or may not follow up with a Warning Letter depending on the firm’s response and the severity of the findings.
Where can I read the full Form 483?: The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.
What is an FDA Form 483?: A Form FDA 483 lists an FDA investigator's written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.
Does this Form 483 mean Wells Pharma of Houston LLC violated the law?: No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.

See if this 483 escalates to a warning letter — before your auditor asks.

Free weekly briefing tracks every FDA inspection outcome.

Full FDA history for Wells Pharma of Houston LLC

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2026). FDA Form 483 — Wells Pharma of Houston LLC (April 13, 2026) — 4 Citations. Digital Empire LLC. Retrieved from https://argushq.ai/483/fda-483-wells-pharma-of-houston-llc-2026-04-13-3016710931

MLA

"FDA Form 483 — Wells Pharma of Houston LLC (April 13, 2026) — 4 Citations." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/483/fda-483-wells-pharma-of-houston-llc-2026-04-13-3016710931.

Chicago

Argus HQ Research. "FDA Form 483 — Wells Pharma of Houston LLC (April 13, 2026) — 4 Citations." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/483/fda-483-wells-pharma-of-houston-llc-2026-04-13-3016710931.

BibTeX

@misc{argushq_argushq_ai_483_fda_483_wells_pharma_of_houston_llc_2026_04_13_3016710931_2026,
  title = {FDA Form 483 — Wells Pharma of Houston LLC (April 13, 2026) — 4 Citations},
  author = {{Argus HQ Research}},
  year = {2026},
  publisher = {Digital Empire LLC},
  url = {https://argushq.ai/483/fda-483-wells-pharma-of-houston-llc-2026-04-13-3016710931},
  note = {Accessed: July 13, 2026}
}

Source: FDA.gov — Inspection Classification Database ↗